SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Tatva Chintan Pharma Chem Ltd

BSE: 543321 NSE: TATVA ISIN: INE0GK401011
  |   Sector:  Chemicals & Fertilizers   |   Industry:  Chemicals

Snapshot

Q.1 Which industry/sub-sector does Tatva Chintan Pharma Chem Ltd belong to?
Tatva Chintan Pharma Chem Ltd belongs to the Chemicals & Fertilizers sector, operating specifically within the Chemicals segment.
Q.2 Is Tatva Chintan Pharma Chem Ltd a good quality company?
Tatva Chintan Pharma Chem Ltd is a average quality company, based on a somewhat consistent 10 year financial track record.
Q.3 Is Tatva Chintan Pharma Chem Ltd undervalued or overvalued?
Tatva Chintan Pharma Chem Ltd appears Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Tatva Chintan Pharma Chem Ltd a good buy now?
Tatva Chintan Pharma Chem Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd revenue growth is -3.2% for FY-2025 , which is below its 5 year CAGR of 7.6% , indicating slower growth.
Q.2 Gross Profit margin of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd Gross profit margin which is the profit after deduction of direct costs, is 7.7% for FY-2025 , which is below its 5 year median of 17.9% , indicating decreasing margins.
Q.3 Operating Profit Margin of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 7.13% for FY-2025 , which is below its 5 year median of 17.74% indicating decreasing margins.
Q.4 Net Profit Margin of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd Net Profit Margin is 0.09% for FY-2025 , is below with its 5 year median of 10.04%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 7.7 17.9
Operating Profit Margin 7.13 17.74
Net Profit Margin 0.09 10.04
Q.5 Return on Asset of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd Return on Asset is 0.04%, which is below its 5 year historical median of 5.75%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd Return on equity is 0.05% for FY-2025 , which is below its historical median of 8.31%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd Return on capital employed is 0.26% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd Cash conversion cycle is 165 days, above its historical median of 165 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.45 0.57
ROE 0.05 8.31
ROCE 0.26 7.49
Cash Conversion Cycle 165 days 165 days
Q.9 Debt to Equity ratio of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd Debt-to-Equity ratio is 0.05 , which is lower with the industry average of 0.13 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd Debt to cash flow from operations is 1.52 , which is at a moderate level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Tatva Chintan Pharma Chem Ltd?
Promoters hold 72.02% of the Tatva Chintan Pharma Chem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Tatva Chintan Pharma Chem Ltd vs industry peers?
Tatva Chintan Pharma Chem Ltd revenue CAGR is 7.62% , compared to the industry median CAGR of 7.7% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 366.4 202
Gross Profit 28.2 23.6
Operating Profit 26 24
Net Profit - 12
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.45 0.93
ROE 0.05 10.18
ROCE 0.26 13.07
Cash Conversion Cycle (days) 164.86 62

Valuation & price assessment

Q.1 Stock return of Tatva Chintan Pharma Chem Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of -8.04% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - -8% 76.2%
Q.3 Valuation ratios of Tatva Chintan Pharma Chem Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 96.39 93.13 41.15
Price to Book 4.01 7.30 2.38
Price to Sales 6.37 8.86 1.93
EV to EBITDA 40.48 56.59 13.71

Check more companies

1. Navin Fluorine Intl
2. Godrej Industries
3. Deepak Nitrite
4. Atul
5. Tata Chemicals
6. BASF India
7. Aarti Inds
8. Aether Industries
9. Deepak Fert & Petro
10. Fine Organic Inds.
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×